Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis by Bota Cui et al.
Cui et al. J Transl Med  (2015) 13:298 
DOI 10.1186/s12967-015-0646-2
RESEARCH
Step-up fecal microbiota transplantation 
strategy: a pilot study for steroid-dependent 
ulcerative colitis
Bota Cui1†, Pan Li1†, Lijuan Xu1, Youquan Zhao2, Huiquan Wang3, Zhaoyuan Peng1, Hai’e Xu4, Jie Xiang1, Zhi He1, 
Ting Zhang1, Yongzhan Nie5, Kaichun Wu5, Daiming Fan5, Guozhong Ji1* and Faming Zhang1*
Abstract 
Background: The strategy of using fecal microbiota transplantation (FMT) for refractory ulcerative colitis (UC) 
remains unclear if single FMT failed to induce remission. This study aimed to evaluate the efficacy and safety of a 
designed step-up FMT strategy for the steroid-dependent UC.
Methods: Fifteen patients with steroid-dependent UC were enrolled, and treated with step-up FMT strategy. Follow-
up clinical data was collected for a minimum of 3 months. Fecal microbiota composition before and post FMT of 
patients and related donors were analyzed by 16S rRNA sequencing.
Results: Eight of fourteen (57.1 %) patients achieved clinical improvement and were able to discontinue steroids fol-
lowing step-up FMT. One patient was lost to follow-up. Among the 8 patients who responded, five (35.7 %) received 
one FMT therapy, one (7.1 %) received two FMTs, and two (14.2 %) received two FMTs plus a scheduled course of ster-
oids. Four (28.6 %) of the 8 patients who responded maintained long-term remission during follow-up (3–18 months). 
Six patients (42.9 %) failed to meet the criteria of clinical improvement and maintained steroid dependence, though 
three experienced transient or partial improvement. Microbiota analysis showed that FMT altered the composition 
greatly, and a microbiota composition highly similar to that of the donor emerged in the patients with successful 
treatment. No severe adverse events occurred during treatment and follow-up.
Conclusions: Step-up FMT strategy shows promise as a therapeutic strategy for patients with steroid-dependent UC, 
likely due to the successful restructuring of gut microbial composition.
Trial registration: ClinicalTrials.gov, Number NCT01790061
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Background
Ulcerative colitis (UC) is a chronic idiopathic inflamma-
tory bowel disease characterized by continuous mucosal 
inflammation with a relapsing and remitting course [1, 
2]. Inducing and maintaining remission on a long-term 
basis are the primary goals of treatment. Corticoster-
oids are among the most effective therapies for patients 
with moderate to severe UC [1, 3]. In the Olmstead 
County cohort of IBD patients, up to forty percent of 
these patients require steroids to control symptoms, 
and at 1  year follow-up approximately twenty percent 
of patients remained steroid dependent [4]. Unfortu-
nately, there are many undesirable side effects of steroids, 
such as infections, hyperglycemia, and bone loss, just to 
name a few. Thus, corticosteroid dependence in patients 
with UC is an important clinical problem and mainte-
nance of steroid-free remission is a key treatment goal. 
Consensus guidelines recommend thiopurines as first 
line steroid-sparing therapy [5, 6]. Biologics therapies, 
such as anti-TNF medications [7, 8], are also effective, 
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though the high costs of such therapies can be prohibi-
tive. Fecal microbiota transplantation (FMT), a concept 
which originated in China a millennia ago [9], involves 
infusing healthy donor microbiota into the intestines of 
a patient to restore the intestinal microbiome. Early stud-
ies have suggested some therapeutic effect (of a single 
FMT) in the treatment of inflammatory bowel disease 
(IBD) including UC and Crohn’s disease (CD) [10–17]. 
However, response rates have not been as impressive as 
FMT for the indication of recurrent Clostridium difficile 
colitis where cure rates approach 90 % [18]. We therefore 
hypothesize that repeat FMT, in conjunction with a short 
course of corticosteroids may lead to better efficacy than 
a single FMT or corticosteroids for treatment of UC.
In 2012, we established a standardized FMT protocol 
and clinical work flow to overcome challenges in the puri-
fication of fecal microbiota from feces and to optimize 
clinical decisions on when or how to use FMT to treat 
IBD [13, 15]. Our previous study showed that the rate 
of clinical improvement and remission in CD patients 
(based on Harvey Bradshaw Index score) following a sin-
gle FMT at the first month was 86.7 and 76.7 % respec-
tively [13].Though there was partial response in patients 
with CD, a single FMT seemed to have limited efficacy 
for steroid dependent patients. Therefore, based on our 
results of single FMT for selected refractory CD [13] and 
our initial experience using FMT to treat UC (clinical 
trial NCT01790061), we designed a protocol of step-up 
FMT strategy for the treatment of steroid-dependent UC. 
This study aimed to evaluate the efficacy and the safety 
of step-up FMT for steroid-dependent UC and to identify 




A prospective observational study as a part of clinical 
trial (NCT01790061) was carried out by the Medical 
Center for Digestive Diseases at the Second Affiliated 
Hospital of Nanjing Medical University, Nanjing, China, 
from November 2012 to August 2014. Informed con-
sent was obtained from all participants. The diagnosis 
of UC was established by a combination of typical clini-
cal, endoscopic, and histological criteria. All included 
patients, had moderate to severe (S2 and S3) UC based 
on the Montreal classification [19]. Steroid dependence 
was defined as either the inability to reduce steroid dose 
below the equivalent of prednisone 10  mg/day within 
3  months of starting steroids without recurrent active 
disease, or relapsing within 3 months of stopping steroids 
in accordance with ECCO guidelines [6]. Exclusion cri-
teria were: severity of Montreal classification below S2; 
accompanied with other severe disease, including other 
intestinal diseases e.g. C. difficile infection, diabetes, can-
cers, and follow-up of less than 3 months.
Stool donors were selected according to the selection 
criteria described in our previous report [13]. Briefly, 
healthy children, age 10–17  years, were selected from 
patients’ relatives or friends, and were carefully screened 
by the following exclusion criteria: history of drug use, 
history of disease (e.g. antibiotic, laxative or diet pill 
use within the past 3  months; prior immunomodula-
tor or chemotherapy use; history of all known infectious 
diseases, morbid obesity, diabetes, IBD, irritable bowel 
syndrome, chronic diarrhea, constipation, colorectal pol-
yps or cancer, immunocompromised states, metabolic 
syndrome, allergy, chronic fatigue syndrome, history of 
major gastrointestinal surgery or systemic autoimmun-
ity, as well as any other diseases or conditions potentially 
associated with changes in intestinal microbiota). In addi-
tion, all patients underwent laboratory evaluation includ-
ing blood test (complete blood count), C-reactive protein, 
erythrocyte sedimentation rate, biochemical tests, Hepa-
titis A IgM, Hepatitis B surface antigen, Hepatitis B core 
IgG and IgM, antibodies, Hepatitis C antibody, human 
immunodeficiency virus types 1 and 2 antibody, Syphilis), 
and stool testing (i.e. stool culture, stool ova and para-
sites). Patients with any laboratory abnormalities were 
excluded.
Purification of fecal microbiota and FMT
The fecal microbiota from donors was purified in our 
laboratory according to our previously published method 
of Filtration plus Centrifugation (FPC) [13]. Four of 14 
patients underwent FMT based on a new developed 
automatic purification system (GenFMTer, FMT Medi-
cal, Nanjing, China). We named this new method for 
enriching microbiota based on an automatic purification 
system microfiltration plus centrifugation (MPC). Pre-
pared microbiota was injected into the distal duodenum 
of recipients through an endoscopic infusion tube (FMT 
Medical, Nanjing, China) inserted into the gastroscope 
channel. The final enriched microbiota in lab and the 
endoscopic image during infusion were shown in Fig. 1. 
One hour prior to FMT, patients were given metoclopra-
mide 10 mg by intramuscular injection and esomeprazole 
magnesium 40  mg intravenously to promote motility of 
the transplanted microbiota into the colon and to inhibit 
the secretion of gastric acid [13].
Step‑up FMT strategy
The step-up FMT strategy was shown in Fig. 2. Before 
FMT, patient characteristics and baseline condition 
were assessed thoroughly. Steroid medications were 
tapered off at least 1 week prior to the first FMT, and 
other medication was also stopped. Patients were 
Page 3 of 12Cui et al. J Transl Med  (2015) 13:298 
encouraged to eat a diet which limited animal protein, 
especially red meats, spicy foods, and high fat food. 
A low residue diet was encouraged. Mesalamine 3.0 g 
was given daily by oral as a sustained treatment before 
and after FMT [13]. Blood and stool samples were 
collected before and after FMT. All patients were fol-
lowed for more than 3  months after the final sched-
uled FMT.
Efficacy and safety assessment
One week after FMT patients were assessed by symp-
toms such as abdominal pain, stool frequency, bloody 
purulent stool, as well as laboratory tests including 
erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), basic chemistries, lymphocytes subset analysis, 
IgG, IgA and IgM. Clinical remission was defined as the 
absence of diarrhea and blood (Montreal classification 
S0); clinical improvement was defined as improvement 
in the severity of Montreal classification by more than 
one grade, e.g. from S3 to S2 or S1 [7]. Sustained clini-
cal response was defined as a persistent steroid-free clini-
cal improvement during follow-up, which was evaluated 
only in patients who achieved short-term clinical benefit. 
Steroid free was defined as absence of symptoms of active 
disease (no abdominal pain, no diarrhea, and no bloody 
purulent stool) without steroids within the next 3 months 
after step-up FMT. Safety was evaluated in all patients by 
recording adverse events during FMT and throughout 
long-term follow-up.
Stool sample collection and bacterial community analysis
Fecal samples from patients and donors were collected 
and stored at −80  °C for microbiota analysis by 16  s 
rRNA sequencing (Illumina, San Diego, CA, USA). Com-
position of fecal bacteria was analyzed at the phylum 
and genus level. Shannon’s diversity index was used to 
indicate the diversity of microbiota. Pearson correlation 
coefficient and principal coordinate analysis (PCoA) were 
Fig. 1 Laboratory enriched fecal microbiota and infusion of fecal microbiota during endoscopy. a The centrifuged microbiota in lab after microfil-
tration. b The final product for infusion. c, d The endoscopic image during infusion showing no observable particles in the suspension fluid under 
magnified endoscopic view, indicating the effect of purification for fecal microbiota
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used to indicate the similarity of microbiota composition 
among samples.
Statistical analysis
Data were analyzed by using SPSS (Chicago, IL, USA) or 
GraphPad (La Jolla, CA, USA). Analyses included paired 
student’s t test for paired data. Two tailed P value was 




A total of 15 patients (Table  1) with steroid-dependent 
active UC (mean 31.7 year-old, range 11–48 years, male/
female 11/4) were enrolled. Mean disease duration was 
4.3  years (range 1–9  years), 13 (86.7  %) of the patients 
had severe (S3) disease and 2 (13.3  %) had moderate 
(S2) UC severity. Eleven (73.3 %) patients had extensive 
lesions. Twelve (80.0 %) patients were being treated with 
other IBD medications besides steroids, such as 5-ASA 
and thiopurines.
Cases serials of FMT
Clinical efficacy of step-up FMT is shown in Table 1. One 
patient (patient 15) was lost for follow-up. Of the remain-
ing 14 patients, 8 (57.1 %) achieved clinical improvement 
and could discontinue steroids following step-up FMT. 
Among these 8 patients, five (35.7 %) received one FMT 
therapy, one (7.1 %) received two FMTs, and two (14.2 %) 
received two FMTs plus one scheduled therapy with 
steroids. Four (28.6  %) of these 8 patients maintained 
long-term remission during follow-up (3–18  months). 
42.9 % (6/14) patients failed to meet criteria for clinical 
improvement or clinical remission and continued to be 
steroid dependent, though some experienced a transient 
improvement or partial decrease in symptom severity.
Two patients (patient 1 and 4) chose to switch therapy 
for being nonresponsive to the first FMT. Three (patient 
2, 3, and 5) had an immediate response to the initial FMT 
but flared within 1 month and then chose to be treated 
with steroids afterwards.
Four patients (patient 7, 9, 13 and 14) received the sec-
ond FMT due to limited efficacy of the first FMT. Patient 
7 had limited response after two FMTs; however he ben-
efited from the steroid treatment after the second FMT 
and was able to withdraw from the steroids successfully. 
His disease flared after being maintained for 4  months’ 
improvement (S3 to S2); however the severity of relapse 
was lower than before FMT. Patient 9 achieved clinical 
improvement (S3 to S2) 7  days after the second FMT, 
which was maintained for 6  months. He then changed 
to TCM (Traditional Chinese medicine) therapy. Patient 
13 had no response to the first FMT, and his second 
FMT was postponed by 3  weeks to allow for drainage 
of a worsening perianal abscess (not related to FMT). 
After the second FMT, he benefited from the scheduled 
steroid therapy and maintained S1 or S0 disease sever-
ity for more than 12  months. Patient 14 had clinical 
improvement (S3 to S1) after two FMTs and achieved 
the remission of multiple skin lesions which was related 
to impaired immunity by long-term steroid use. He was 
given a scheduled course of steroid therapy not because 
of his intestinal symptoms, but for fatigue.
Response to FMT
As shown in Fig. 3, the overall score for abdominal pain 
and stool frequency decreased after FMT. Patients who 
experienced disease flare within 1  month of FMT had 
CRP, ESR, white blood cells (WBC) and lymphocyte sub-
group populations that did not change following FMT 
(Additional file  1: Table  S1). In contrast, patients who 
achieved clinical improvement and clinical remission had 
significantly lower ESR than those without response to 
FMT (t test, P < 0.05). CRP also showed a similar trend, 
but no statistical difference was observed (Additional 
file  1: Table  S1).We recommended follow-up endoscopy 
at our center at 3 or 6 months after step-up FMT. How-
ever, two cases refused due to symptoms and six due to 
the long distance to our hospital from their home. Thus 
only five cases underwent colonoscopy at 3 months after 
step-up FMT. In all five cases, the severity of colitis was 
markedly improved after FMT, but the improvement was 
Fig. 2 Flow chart of step-up FMT for steroid-dependent UC. The 
strategy includes three steps: 1 the initial FMT; 2 a second FMT after 
1 week; 3 one short course of steroid therapy. Patients who fail to 
benefit from step 1 are advised to receive the second FMT. Patients 
who still had no response were switched to one-phase therapy using 
steroids. Withdrawal of corticosteroid started after 2–4 weeks of full 
dose of steroids. The patients who failed to benefit from each step 
could also choose biologic therapy or resumption of steroid therapy
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not reflected by Mayo score. Therefore, based on the pre-
liminary FMT experience and ethic consideration, we did 
not suggest each patient to accept colonoscopy 3 months 
after FMT.
Fecal microbiota analysis
The changes of intestinal microbiota were analyzed in 
fecal samples from four patients (patient 6, 9, 10, and 13) 
and their related donors (patient 6 and 10 shared the same 
donor).These patients achieved clinical improvement and 
were steroid-free after therapy. The other patients came 
from all over the entire nation of China, and it was there-
fore inconvenient for them to re-visit, hence fecal samples 
post-FMT could not be obtained in our lab.
The alteration of microbiota in steroid‑dependent UC 
patients
As shown in Fig. 4a, prior to FMT, the diversity of fecal 
microbiota of patients (n = 4) was decreased compared 
to donors (n  =  3) (P  =  0.004). Figure  4b demonstrates 
the composition of fecal microbiota based at the phy-
lum level. The major bacteria of the donors were clas-
sified as Firmicutes (62.3  ±  11.5  %) and Bacteroidetes 
(32.7  ±  11.6  %), which comprised 95  ±  1.1  % of the 
total fecal microbiota. The characteristics of bacte-
rial composition in UC patients showed an imbalanced 
ratio of Firmicutes and Bacteroidetes and an increase of 
Proteobacteria.
Change of intestinal microbiota after FMT
Figure  5a indicated the time-point of stool sample col-
lected, and Fig.  5b showed the change of the bacterial 
diversity after FMT. The bacterial diversity after FMT 
increased in patient 6, 9 and 10, and was reduced in 
patient 13, likely due to antibiotics used before the sec-
ond FMT.
Analysis of microbiota composition at the phylum 
(Fig.  5c) and genus (Fig.  6) level indicated significant 
reconstruction of the bacterial composition following 
FMT. Except for patient 13 who had used antibiotics, 
Fig. 3 Clinical response to step-up FMT. a Abdominal pain scores of patients with steroid-dependent UC at baseline and the first week after 
initial FMT (n = 15). 10 patients showed significant improvement of abdominal pain after FMT. b Abdominal pain score at baseline and through-
out follow-up after step-up FMT (n = 15); c frequency of patients’ defecation before and at 1 week after initial FMT (n = 15), 12 patients showed 
improvement in stool frequency; d change in defecation frequency at baseline and throughout follow-up after step-up FMT (n = 15)
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the composition of microbiota in patient 6, 9 and 10 all 
showed a trend similar to their related donors. The analy-
sis of Pearson correlation coefficient and PCoA indicated 
the same trend (Fig. 7), especially in patient 6, the Pearson 
correlation coefficient of the patient-donor comparison at 
4  months after FMT was 0.94 (Fig.  7a), which indicated 
the high similarity of microbiota composition between 
them.
Fig. 4 Analysis of fecal microbiota of patients with steroid-dependent UC. a The diversity of fecal microbiota (Shannon’s diversity index) showed 
significant decrease in steroid-dependent UC compared with healthy donors (*P < 0.05); b fecal microbiota composition at the phylum level in 
patients with steroid-dependent UC and in healthy donors
Fig. 5 Change of fecal microbiota composition after FMT at a phylum level. a The schedule of fecal sample collection; b change in Shannon’ diver-
sity index before and after FMT; c analysis of fecal microbiota composition at the phylum level before and after FMT
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Fig. 6 Genus level change in fecal microbiota composition following (two) FMTs in ulcerative colitis patients who are steroid-dependent
Fig. 7 Similarity of fecal microbiota composition at the genus level. a Changes in Pearson correlation coefficient at the genus level. Pearson correla-
tion coefficient ranged from 0 (red) to 1 (green). When the value between two samples is close to 1, the compositions are more similar. b Principal 
coordinate analysis (PCoA) of (Unifrac distance between) fecal microbiota before and after FMT. The distance between the samples represents the 
similarity of micobiota composition; a closer distance indicates higher similarity. Patient 6 and patient 10 shared the same donor (donor 1)
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Patient 13 suffered from perianal abscess due to long-
term steroid use, and did not benefit from the first FMT. 
A thread-drawing surgery was presented at 7  days after 
the first FMT, and antibiotics were given before and after 
surgery. The results of our fecal microbiota analyses indi-
cate that use of antibiotic affected the diversity and com-
position of fecal microbiota greatly.
Safety of FMT
There were no severe adverse events during and after 
FMT procedure. Two patients were observed with fever 
(less than 39 °C) within 6 h after FMT, and two had tran-
sient increase in diarrhea frequency within 24  h after 
FMT. All symptoms disappeared within 1 day without any 
medical intervention. One patient had a mild testicular 
pain after each of two FMTs, which resolved within 12 h.
Discussion
Our previous study [13] reported the role of intestinal 
bacterial reconstruction in the treatment of selected 
refractory CD. This study further explored the role of 
step-up FMT in steroid-dependent UC. Overall, 57.1  % 
of recruited patients achieved clinical improvement 
and sustained steroid independence after step-up FMT 
and 28.6  % of patients maintained long-term remission 
(3–18 months). These results indicate that step-up FMT 
can lead to steroid-free clinical improvement or remis-
sion in patients with steroid-dependent UC.
Patients with steroid-dependent UC are considered 
immunocompromised (IC). Therefore, the use of FMT 
for steroid dependent patients had been limited due 
to concerns about safety in this population. Published 
guidelines recommend avoidance of FMT in solid organ 
transplant patients [20] and specified that considerations 
for increased risk in patients on major immunosuppres-
sive agents or patients with severe immunodeficiency [21]. 
A retrospective study [22] assessed the safety of FMT for 
immunocompromised patients with CDI which involved 
HIV/AIDS, solid organ transplant, oncologic condition, 
immunosuppressive therapy for IBD and other medical 
conditions or medications. It was reported that while 15 % 
patients had serious adverse events, none suffered infec-
tions which were related to FMT. Brandt et  al. [23] pub-
lished similar results in immunocompromised patients 
with IBD being treated with FMT. In this study, no severe 
or obvious adverse events were reported, further strength-
ening the case that FMT can be performed safely in IC 
patients. It is noted, however, that in this study steroids 
were stopped in all the patients at least 1 week before FMT.
A meta-analysis [24] on the FMT in IBD had demon-
strated 22  % of patients achieved clinical remission after 
FMT, while a systemic review [17] concluded that FMT 
had a success rate close to 90 % in patients with UC. In the 
present study, 57.1 % of patients achieved clinical improve-
ment and 28.6  % had clinical remission. However, Kump 
et  al. [25] reported that FMT did not induce remission in 
the patients with chronic active UC, and De Leon et al. [26] 
reported a patient with UC that had been quiescent for long 
time who developed a transient flare after treatment of CDI 
by FMT. The main reason of variable results is unknown, 
though a recent study by Moayyedi et al. suggests that donor 
stool composition may play an important role.
We believe that FMT via colonoscopy or enema is sub-
optimal for patients with extensive UC as they frequently 
have a difficult time retaining the infused microbiota 
suspension. In this study, FMT was performed based on 
a defined volume of purified fecal microbiota according 
to the established protocol of a standardized lab [13], and 
the fecal microbiota was delivered into patient’s mid-gut 
through an esophagogastroduodenoscope.
Three patients who had failed to benefit from the first 
FMT, improved after the second FMT or after the sec-
ond FMT plus a short course of steroid treatment. This 
further suggests that sequential therapy might be an 
effective strategy for the steroid-dependent UC patients. 
Weingarden’s study [27] for FMT in the treatment of CDI 
also showed limited efficacy of single FMT performing 
for acute CDI, and delaying FMT or performing a second 
FMT following a course of anti-CDI therapy resulted in 
better clinical outcomes.
Dysbiosis in patients with IBD reflect a dominance 
of potentially pro-inflammatory pathogens over anti-
inflammatory commensals, which may induce a shift 
in the immunological balance of the intestinal mucosa 
toward inflammation [28–30]. It remains unclear 
whether the dysbiosis of IBD is primarily responsible 
for the activation of immune system and subsequent 
inflammation or is a consequence of colitis caused by 
altered bacterial growth conditions [28, 31]. In this study, 
a reversal of some of the reported dysbiotic changes in 
the fecal microbiota was observed in patients after FMT, 
including marked increase in compositional diversity, 
decrease in Proteobacteria, and the normalization of 
the Firmicutes to Bacteroidetes ratio. The four patients 
whose fecal microbiota was analyzed by deep sequencing 
achieved clinical improvement or remission after FMT. 
Two (patient 9 and 13) of them underwent two FMTs 
due to limited efficacy of the first FMT, and the change 
of microbiota composition was also limited after the first 
treatment, while the other two patients (patient 6 and 
10) showed obvious response to the first FMT. In all four 
cases there was obvious restructuring of the intestinal 
microbiota following FMT. The phenomenon might indi-
cate the degree of microbiota reconstruction was related 
to the clinical response in the patients with steroid-
dependent UC. The major limitation of our study was the 
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missing analysis of microbiota composition from patients 
who did not respond to FMT and their corresponding 
donors.
Numerous strategies such as immunomodulators, bio-
logic therapy and surgery [4, 7, 32, 33] are available to 
induce and sustain remission in steroid-dependent UC. 
This study suggests that step-up FMT might be an added 
therapy for this challenging patient population despite 
the study weaknesses, such as the limited cases, absence 
of control group, and insufficient endoscopic evaluation 
for each case during follow-up. Multi-center randomized 
clinical trials with larger sample size and long-term follow 
up should be performed to provide a clearer conclusion. 
Further research is required to explore the mechanisms of 
step-up FMT, especially understanding the role of restor-
ing microbiota and its effects on host immunity.
FMT provided therapeutic options for patients with 
IBD; however, not each patient can benefit from single 
FMT. This study indicated the light of step-up FMT strat-
egy using repeat FMT and steroids for steroid-dependent 
UC. We hypothesize that step-up FMT strategy should 
be a concept, which means, FMTs can not only com-
bine with steroids but also other potential therapy, such 
as anti-TNFα antibody. Actually, based on this step-up 
strategy, an observational study of using FMT in con-
junction with biologics therapies for IBD is ongoing in 
our center. We will report the results in the future.
Conclusion
This pilot study reports a novel concept of using the step-
up FMT strategy for the patients with steroid-dependent 
UC. The efficient treatment might be due to the success-
ful reconstruction and maintenance of intestinal microbi-
ota. The present prospective study provides preliminary 
evidence for supporting our hypothesis that step-up 
FMT might be a key therapy in the treatment of IBD.
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